Talene A Yacoubian

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. pmc IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation
    Talene A Yacoubian
    Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA and Civitan International Research Center 560D, 1719 6th Avenue South, Birmingham, AL 35294, USA Tel 1 205 996 7543
    Neurodegener Dis Manag 3:123-131. 2013
  2. pmc Transcriptional dysregulation in a transgenic model of Parkinson disease
    Talene A Yacoubian
    Neurology Department, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Neurobiol Dis 29:515-28. 2008
  3. pmc Racial differences in Parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: a cross-sectional study
    Talene A Yacoubian
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
    Neuroepidemiology 33:329-34. 2009
  4. pmc Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease
    T A Yacoubian
    Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cell Death Dis 1:e2. 2010
  5. pmc Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice
    Trent U Steidinger
    Department of Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS ONE 8:e56092. 2013
  6. pmc 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening
    Nicholas J Lavalley
    Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Hum Mol Genet 25:109-22. 2016
  7. pmc A neuroprotective role for angiogenin in models of Parkinson's disease
    Trent U Steidinger
    Department of Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Neurochem 116:334-41. 2011
  8. doi request reprint Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease
    Adam J Harrington
    Department of Biological Sciences, The University of Alabama, Tuscaloosa, Alabama 35487, USA
    J Neurosci 32:2142-53. 2012
  9. pmc 14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax
    Sunny R Slone
    Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS ONE 6:e21720. 2011
  10. pmc Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity
    Liyan Qiao
    Department of Pathology, University of Alabama at Birmingham, USA
    Mol Brain 1:17. 2008

Collaborators

Detail Information

Publications13

  1. pmc IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation
    Talene A Yacoubian
    Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA and Civitan International Research Center 560D, 1719 6th Avenue South, Birmingham, AL 35294, USA Tel 1 205 996 7543
    Neurodegener Dis Manag 3:123-131. 2013
    ..While it has also been shown to be effective in early PD compared with placebo, its role in early PD compared with other available medications for PD is unclear at this time...
  2. pmc Transcriptional dysregulation in a transgenic model of Parkinson disease
    Talene A Yacoubian
    Neurology Department, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Neurobiol Dis 29:515-28. 2008
    ..These data demonstrate that alterations of gene expression are widespread in this animal model, and suggest that transcriptional dysregulation may be a disease mechanism that can be targeted therapeutically...
  3. pmc Racial differences in Parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: a cross-sectional study
    Talene A Yacoubian
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
    Neuroepidemiology 33:329-34. 2009
    ..We evaluated data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study to describe potential racial differences in PD prevalence...
  4. pmc Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease
    T A Yacoubian
    Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cell Death Dis 1:e2. 2010
    ....
  5. pmc Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice
    Trent U Steidinger
    Department of Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS ONE 8:e56092. 2013
    ..Together, these findings extend the evidence for protective effects of angiogenin in vitro, but also suggest that further study of in vivo models is required to translate these effects into meaningful therapies...
  6. pmc 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening
    Nicholas J Lavalley
    Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Hum Mol Genet 25:109-22. 2016
    ..Taken together, we conclude that 14-3-3θ can regulate LRRK2 and reduce the toxicity of mutant LRRK2 through a reduction of kinase activity. ..
  7. pmc A neuroprotective role for angiogenin in models of Parkinson's disease
    Trent U Steidinger
    Department of Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Neurochem 116:334-41. 2011
    ..Together our data supports the importance of angiogenin in protecting against dopaminergic neuronal cell death and suggests its potential as a therapy for PD...
  8. doi request reprint Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease
    Adam J Harrington
    Department of Biological Sciences, The University of Alabama, Tuscaloosa, Alabama 35487, USA
    J Neurosci 32:2142-53. 2012
    ..Our results support hVPS41 as a potential novel therapeutic target for the treatment of synucleinopathies like PD...
  9. pmc 14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax
    Sunny R Slone
    Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS ONE 6:e21720. 2011
    ..These data suggest that 14-3-3θ's neuroprotective effects against rotenone are at least partially mediated by Bax inhibition and point to a potential therapeutic role of 14-3-3s in Parkinson's disease...
  10. pmc Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity
    Liyan Qiao
    Department of Pathology, University of Alabama at Birmingham, USA
    Mol Brain 1:17. 2008
    ..Our data identify a conserved CD function in α-syn degradation and identify CD as a novel target for LB disease therapeutics...
  11. pmc LRRK2 secretion in exosomes is regulated by 14-3-3
    Kyle B Fraser
    Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics
    Hum Mol Genet 22:4988-5000. 2013
    ..Together, these results define a pathway for LRRK2 extracellular release, clarify one function of the LRRK2 14-3-3 interaction and provide a foundation for utilization of LRRK2 as a biomarker in clinical trials. ..
  12. pmc α-Synuclein overexpression represses 14-3-3θ transcription
    Huiping Ding
    Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Civitan International Research Center 560D, 1719 6th Avenue South, Birmingham, AL, 35294, USA
    J Mol Neurosci 51:1000-9. 2013
    ..These findings suggest that α-synuclein represses 14-3-3θ transcription under pathologic conditions, but that regulation of 14-3-3θ expression is not a function of endogenous α-synuclein at baseline. ..
  13. pmc Targets for neuroprotection in Parkinson's disease
    Talene A Yacoubian
    Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Biochim Biophys Acta 1792:676-87. 2009
    ....